-
Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem
•
Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo Municipality, announced at the World Digital Economy Conference 2022. The collaboration aims to enhance Ningbo’s healthcare digital infrastructure and data utilization, with no financial terms disclosed.Partnership Goals The alliance will focus on three pillars:Upgrading health…
-
Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker, will invest RMB 50 million (USD 7.2 million) in compatriot firm Cardiotek HK Ltd, securing a 9.09% stake. The deal underscores Bio-Heart’s expansion into transcatheter aortic valve replacement (TAVR) technology, complementing its core bioresorbable scaffold…
-
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
•
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary, Vernalis Research, and U.S.-based Unison Medicines Inc., targeting an undisclosed bacterial pathogen previously deemed “undruggable.” The partnership leverages Vernalis’ drug discovery expertise to design small-molecule therapies, with Unison funding all R&D activities and sharing downstream…
-
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a universal booster shot. The study demonstrated superior neutralizing antibody responses against the wild strain and Omicron subvariants BA.1/BA.2 compared to homologous inactivated vaccine boosters. Trial Design and ResultsThe…
-
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
•
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of fezolinetant, its experimental therapy for menopause symptoms, in China. The 52-week MOONLIGHT 3 study met primary endpoints for safety and efficacy in treating severe vasomotor symptoms (VMS), positioning the drug as a potential first-in-class treatment…
-
CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development
•
CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has signed a global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” chimeric antigen receptor macrophages (CAR-iMACs) for cancer immunotherapy. Financial terms of the agreement were not disclosed. Strategic Partnership and R&D SynergiesThe partnership combines CellOrigin’s expertise…
-
Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular devices, has announced plans for an initial public offering (IPO) on Shanghai’s Sci-Tech Innovation Board (STAR) following its HKD 440 million (USD 56 million) Hong Kong debut in November 2023. The move underscores the company’s…
-
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd—a subsidiary of Fosun International—is set to sell a holding of 80 million shares, or a 3% stake, in the firm. The sale is expected to bring in RMB 3.22 billion…
-
SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC
•
China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in the Phase III regulatory REPLATINUM study in China for its RRx-001, a next-generation small-molecule immunotherapy targeting CD47/SIRPα (signal-regulatory protein alpha). The drug, in-licensed from US firm EpicentRx Inc. in July 2020, is being evaluated as…
-
Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits
•
Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United Kingdom. The company’s monkeypox virus antigen detection kit, utilizing a colloidal gold method, has been approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for marketing. Additionally, its novel coronavirus (2019-nCoV) antigen detection…
-
Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III ZGDD3 study for its Category 1 anti-cancer drug donafenib in locally advanced/metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Study Details and ResultsA total of 191 patients were enrolled in the ZGDD3 study, with 128 in the…
-
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
•
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up to RMB 3.97 billion (USD 572 million) via private placement, with proceeds allocated to novel drug R&D and construction of its headquarters and R&D facilities. The move underscores the firm’s ambition to accelerate pipeline development…
-
CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines
•
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have received emergency use authorizations (EUAs) from Chinese regulators for their respective COVID-19 vaccines as sequential booster shots. The approvals expand the country’s arsenal of heterologous boosters amid rising demand for enhanced protection. CanSino’s Inhaled VaccineCanSino’s…
-
AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center
•
Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China Beijing International Fair for Trade in Services (CIFTIS) to establish a smart manufacturing and biomedical digital empowerment center. The initiative, leveraging AWS’s cloud, AI, and IoT technologies, aims to accelerate industrial upgrading in the Guangdong…
-
BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion
•
China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300 million (USD 43.2 million) in a Series A financing round led by Sequoia China. The funding will accelerate clinical development, regulatory filings, and global expansion of its pipeline targeting brain, pancreatic, prostate, and other tumors.…
-
Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical trial of its JAK inhibitor, jacktinib, for severe alopecia areata, marking the second IND clearance for the drug in the U.S. The therapy targets immune-driven inflammation via JAK/STAT pathway inhibition. Drug Profile and MechanismJacktinib, a…
-
Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy
•
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a Phase I/IIa trial of its CD73 monoclonal antibody (mAb), JAB-BX102, for advanced solid tumors. The study, cleared by Chinese regulators in March 2022, marks the drug’s global clinical debut after U.S. approval in October 2021.…
-
Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development
•
China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome to develop the latter’s preclinical monoclonal antibody, MAb11-22.1, for antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR)-T cell therapies. The deal follows Northeast’s 2017 in-licensing of a Herceptin biosimilar from MedAbome. Collaboration TermsUnder the agreement,…
-
Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022
•
China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates KN046 and KN026 at the European Society for Medical Oncology (ESMO) 2022 conference. The programs target multiple cancers, including non-small cell lung cancer (NSCLC) and HER2-positive gastric cancer, with results showing promising efficacy and safety…
